Association between Prescription and Control Status of Dyslipidemia and Hypertension among Japanese Patients with Diabetes.


Journal

Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298

Informations de publication

Date de publication:
01 Sep 2019
Historique:
pubmed: 7 2 2019
medline: 15 2 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

The proper management of atherosclerotic risk factors (ARFs) and attainment of target levels (TLs) for ARFs are crucial in preventing atherosclerotic cardiovascular disease (ASCVD). In this study, utilizing data from the "Specific Health Check and Guidance in Japan," which was conducted from 2008 to 2011, we examined TL attainment status of low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) and prescription status of dyslipidemia and hypertension in patients with diabetes undergoing medical treatment, and analyzed the factors that affected prescription status. Subjects receiving medical treatment for diabetes were selected from the database. Subjects were classified by prescription status for dyslipidemia and hypertension, and TL attainment status was assessed for each ARF. The percentage of subjects who did not attain TLs and were not under medication was higher for LDL-C than for BP. The un-prescribed rates among non-TL-attained subjects were 60%-75% for LDL-C, and around 30%-40% for BP. The un-prescribed rates to those who were qualified for prescription therapy were also higher for LDL-C than for BP. Logistic regression analyses revealed that the subjects who were prescribed for dyslipidemia had the following characteristics compared with the un-prescribed non-TL-attained subjects: older age, higher body mass index, lower estimated glomerular filtration rate, previous heart or cerebrovascular disease, and higher medication rate for other ARFs. The present study revealed that, in Japan, the adequate prescription rate for dyslipidemia was lower than that for hypertension in patients with diabetes, suggesting the proper prescription therapy for dyslipidemia should be pursued to further prevent ASCVD.

Identifiants

pubmed: 30726791
doi: 10.5551/jat.47597
pmc: PMC6753245
doi:

Substances chimiques

Antihypertensive Agents 0
Hypolipidemic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

805-820

Références

N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Arch Intern Med. 2009 Feb 9;169(3):260-8
pubmed: 19204217
Hypertens Res. 2009 Jan;32(1):3-107
pubmed: 19300436
Clin Exp Nephrol. 2012 Apr;16(2):244-9
pubmed: 22057582
Hypertens Res. 2013 Apr;36(4):328-33
pubmed: 23171953
J Atheroscler Thromb. 2013;20(6):517-23
pubmed: 23665881
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
Am J Cardiol. 2014 May 15;113(10):1765-71
pubmed: 24792743
PLoS One. 2014 Sep 30;9(9):e108718
pubmed: 25268956
J Atheroscler Thromb. 2016 Aug 1;23(8):991-1003
pubmed: 26961112
JAMA. 2016 Apr 19;315(15):1580-90
pubmed: 27039291
Atherosclerosis. 2016 Aug;251:248-254
pubmed: 27419905
J Hypertens. 2017 Sep;35(9):1808-1815
pubmed: 28486272
Atherosclerosis. 2018 May;272:145-152
pubmed: 29604481
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Diabetes. 1996 Jul;45 Suppl 3:S14-6
pubmed: 8674881
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301

Auteurs

Miki Sakamoto (M)

Department of Internal Medicine, Teikyo University.

Naoki Edo (N)

Department of Internal Medicine, Teikyo University.

Satoshi Takahashi (S)

Department of Internal Medicine, Teikyo University.

Erina Okamura (E)

Department of Internal Medicine, Teikyo University.

Kenji Uno (K)

Department of Internal Medicine, Teikyo University.

Koji Morita (K)

Department of Internal Medicine, Teikyo University.

Toshio Ishikawa (T)

Department of Internal Medicine, Teikyo University.

Koichi Asahi (K)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Kunitoshi Iseki (K)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Toshiki Moriyama (T)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Kunihiro Yamagata (K)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Kazuhiko Tsuruya (K)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Shouichi Fujimoto (S)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Ichiei Narita (I)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Tsuneo Konta (T)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Masahide Kondo (M)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Kenjiro Kimura (K)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Yasuo Ohashi (Y)

Department of Integrated Science and Engineering for Sustainable Society, Chuo University.

Tsuyoshi Watanabe (T)

Steering Committee for "Design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkups".

Kazuhisa Tsukamoto (K)

Department of Internal Medicine, Teikyo University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH